期刊文献+

非肌层浸润性膀胱尿路上皮癌复发风险的多因素分析 被引量:2

Multivariate analysis of recurrence factors for non-muscle-invasive bladder urothelial carcinomas
原文传递
导出
摘要 目的探讨影响非肌层浸润性膀胱尿路上皮癌复发的相关因素及其临床意义。方法回顾性分析中山大学附属第一医院泌尿外科2003年1月至2009年2月收治的161例非肌层浸润性膀胱尿路上皮癌患者的生存资料,采用Kaplan-Meier法、Log-rank检验及COX比例风险模型对年龄、性别、肿瘤分期、分级、大小、数目及其生长部位、术后维持灌注用药及既往复发情况等影响肿瘤复发的因素进行统计分析。结果单因素分析表明不同肿瘤分期、肿瘤分级、肿瘤数目及既往复发情况间肿瘤复发差异均有统计学意义(均P〈0.05),纳入COX回归模型后得提示肿瘤复发的危险因素为:肿瘤分期(RR=3.810,P=0.001)、肿瘤分级(RR=2.416,P=0.009)、既往复发情况(RR=1.810,P=0.010)、肿瘤数目(RR=1.736,P=0.036)。结论肿瘤分期分级对非肌层浸润性膀胱尿路上皮癌复发影响最大,既往复发情况及肿瘤数目也是复发的相关因素。 Objective To discuss the risk factors of recurrent non-muscle-invasive bladder cancer and elucidate its clinical significance. Methods The retrospective survival analysis of 161 patients with non- muscle-invasive bladder cancer was performed by Kaplan-Meier method, Log-rank test and COX proportional hazard model. Results On univariate analysis, the parameters of tumor stage, tumor grade, number of tumors and previous recurrence were significant for tumor recurrence ( all P 〈 0. 05 ). On multivariate analysis of COX proportional hazard model, all the above risk factors remained significant for tumor recurrence. The hazard ratios were as follows : tumor stage (RR = 3. 810, P = 0. 001 ) , tumor grade ( RR = 2. 416, P = 0. 009) , number of tumors (RR = 1. 736, P =-0. 036)and previous recurrence (RR = 1.810, P = 0. 010). Conclusion Tumor stage and tumor grade plays the most important role in tumor recurrence.
出处 《中华医学杂志》 CAS CSCD 北大核心 2010年第28期1992-1994,共3页 National Medical Journal of China
基金 广东省自然科学基金(915001002000004)
关键词 膀胱肿瘤 复发 多因素分析 Bladder neoplasms Recurrence Multivariate analysis
  • 相关文献

参考文献14

  • 1Louis R,Andrew C,Atan W,et al.Campbell-Walsh Urology.9th ed.USA:Elsevier Inc,2007:2447-2467.
  • 2Burger M,van der Aa MN,van Oers JM,et al.Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status:a prospective study.Eur Urol,2008,54:835-844.
  • 3Sorbin DH,Witteking CH.TNM classification of Malignant Tumors.6th ed.New York:Wiley-Liss,2002:199-202.
  • 4Oosterlinck W,Witjes F,Sylvester R,et al.Diagnostic and prognostic factors in non-mnscle-invasive bladder cancer and their influence on treatment and outcomes.Eur Urol,2008,7 Suppl 7:516-523.
  • 5Louis LS.Urethelial cancer biomarkers for detection and surveillance.Urology,2006,67(3Suppl 1):25-34.
  • 6Mitra AP,Datar RH,Cote RJ.Molecular pathways in invasive bladder cancer:new insights into mechanisms,progression,and target identification.J Clin Oncol,2006,24:5552-5564.
  • 7朱育焱,孔垂泽,曾宇,庞国友,杨春明,孙志熙.细胞黏附、多药耐药及细胞增殖在T_1G_3型浅表膀胱癌近期复发中的作用[J].中华外科杂志,2003,41(12):893-896. 被引量:9
  • 8张玉石,李汉忠,张锐强,石冰冰.T1G3膀胱移行细胞癌复发特点分析[J].中华医学杂志,2006,86(19):1305-1308. 被引量:3
  • 9Queipo Z,Ruiz C,Palmere M,et al.Prognostic value for progression of the regulating p roteins of the cellular cycle in PT1G3 bladder tumors.Actas Urol Esp,2005,29:261-268.
  • 10Solsona E,Iborra I,Dumont R,et al.The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.J Urol,2000,164:685-689.

二级参考文献32

  • 1肖泽均,郑闪,陈汶,张海峰,李长岭,高燕宁.Survivin蛋白在膀胱移行细胞癌组织中的表达及临床意义[J].中华医学杂志,2004,84(23):1977-1979. 被引量:7
  • 2Serth J, Kuczyk MA, Bokemeyer C, et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer, 1995. 71 : 201-205.
  • 3Lipponen PK, Eskelinen MJ. Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol, 1995, 121 : 303-306.
  • 4Shariat SF, Pahlavan S, Baseman AG, et al. E-cadlherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder.Urology, 2001, 57: 60-65.
  • 5Zhang HT, Craft P, Scott PA, etal. Enhancement of tumor growth and vascularity by transfection of vascular endothelial growth factor into MCF-7 cells breast carcinoma cells. J Nail Cancer Inst, 1995, 87: 213-219.
  • 6Chow NH, Liu HS, Chan SH, et al. Expression of vascular endolhelial growth factor in primary superficial bladder cancer. Anticancer Res,1999. 19: 4593-4597.
  • 7Pycha A, Mian C, Hoibauer J, et al. Multifocality of transitional cellcarcinoma results from genetic instability of entire transitional epithelium.Urology, 1999, 53: 92-97.
  • 8Andres RA, Salvador PF, Joaquin GG, et al. Multivariate analysis of survival recurrence progression and development d metastasis in T1 andT2a Transitional Cell Bladder Carcinoma. Cancer, 2002.94: 1677-1684.
  • 9Allard P, Bemard P, Frader Y, et al. The early clinical course of primary Ta and T1 bladder cancer : a proposed prognostic indet. Br J Urol, 1998, 81: 692-698.
  • 10Holmang S, Hedelin H, Anderstrom C, et al. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol, 1995, 153: 1823-1827.

共引文献25

同被引文献30

  • 1van Rhijn B W, Burger M, Lotan Y, et al. Recurrenceand progression of disease in non-muscle-invasive blad der cancer: from epidemiology to treatment strategy [J]- Eur Urol, 2009,56:430-442.
  • 2Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update[J]. Eur Urol, 2011, 59:997-1008.
  • 3Sylvester R J, van der Meijden A P, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2 596 patients from seven EORTC trials[J]. Eur Urol, 2006,49: 466- 465; discussion 475-477.
  • 4Matsuda T, Katanoda K. Comparison of time trends in bladder cancer incidence (1973-1997) in East Asia, Eu- rope and USA, from Cancer Incidence in Five Conti- nents Vol. IV-I-J]. Jpn J Clin Oncol, 2008,38:85- 86.
  • 5Herncindez V, De La Pefla E, Martin M D, et al. Ex- ternal validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer [J ]. World J Urol, 2011,29:409-414.
  • 6Sakano S, Matsuyama H, Takai K, et al. Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European As- sociation of Urology guidelines [J]. BJU Int, 2011, 107,1598-1604.
  • 7Shi B, Zhang K, Zhang J, et al. Relationship between patient age and superficial transitional cell carcinoma characteristics[J]. Urology, 2008,71 : 1186- 1190.
  • 8Fernandez-Gomez J, Madero R, Solsona E, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasivebladder cancer treated with bacillus Calmette-Gurin: external validation of the EORTC risk tables [J]. Eur Urol, 2011,60:423-430.
  • 9Sylvester R J, Oosterlinck W, van der Meijden A P. A single immediate postoperative instillation of chemo- therapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of pub lished results of randomized clinical trials[J]. J Urol, 2004,171:2186-2190, quiz 2435.
  • 10Pawinski A, Sylvester R, Kurth K H, et al. A com- bined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Coun- cil randomized clinical trials {or the prophylactic treat- ment of stage TaT1 bladder cancer. European Organi- zation for Research and Treatment of Cancer Genitouri- nary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer[J]. J Urol, 1996,156:1934-1940, discussion 1940-1941.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部